A blinded pathology re-review confirmed the presence of non-high-grade serous or non-grade 2/3 endometrioid histologies in 11 of the 14 cases, while all cancers with KRAS, NRAS, or BRAF mutations and a TP53 alteration (n = 7) were confirmed to be high-grade serous (Supplementary Table S12 and Supplementary Fig. S8). This evidence concerns the gene KRAS and cancer.